Rothschild & CO Asset Management Us Inc. Tcr2 Therapeutics Inc. Transaction History
Rothschild & CO Asset Management Us Inc.
- $6.56 Billion
- Q4 2022
Shares
5 transactions
About TCR2 THERAPEUTICS INC.
- Ticker TCRR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 38,606,400
- Description
- TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...